Dimethyl fumarate °æ±¸Á¦(Ç°¸í: ÅØÇǵ¥¶óĸ½¶) ¡á °í½Ã °³Á¤ Àüü³»¿ë Çã°¡»çÇ× ¹üÀ§ ³»¿¡¼ ¾Æ·¡¿Í °°Àº ±âÁØÀ¸·Î Åõ¿© ½Ã ¿ä¾ç±Þ¿©¸¦ ÀÎÁ¤Çϸç, µ¿ ÀÎÁ¤±âÁØ ÀÌ¿Ü¿¡´Â ¾à°ª Àü¾×À» ȯÀÚ°¡ ºÎ´ãÅä·Ï ÇÔ. - ¾Æ ·¡ - °¡. Åõ¿© ´ë»ó ½Å°æ°úÀü¹®ÀÇ°¡ ÁøÂûÇÏ¿© McDonald(`17) Áø´Ü±âÁØ(½Ã°£ÆÄÁ¾(Dissemination in time, DIT)°ú °ø°£ÆÄÁ¾(Dissemination in space, DIS)À» ÃæÁ·)¿¡ ºÎÇÕÇÏ¸é¼ ´Ù¸¥ À¯»çÁúȯ¿¡ ÀÇÇÑ ¹ß»ýÀ» ¹èÁ¦ÇÒ ¼ö ÀÖ´Â ¿Ü·¡Åë¿øÀÌ °¡´ÉÇÑ(º¸Çà °¡´ÉÇÑ) Àç¹ß¿ÏÈÇü ´Ù¹ß°æÈÁõ ȯÀÚ(RRMS) ³ª. Åõ¿©ÁßÁö ±âÁØ 1) ½Å°æ°úÀü¹®ÀÇ°¡ ÁøÂûÇÏ¿© 12°³¿ù À̳»¿¡ 2ȸÀÇ ½ÉÇÑ ¼Õ»óÀÌ À¯¹ßµÇ´Â Àç¹ßÀÌ ÀÖ´Â °æ¿ì(Two disabling relapses, as defined by the examining neurologist, within a 12 month period) 2) 6°³¿ù¿¡ °ÉÃÄ °üÂûÇÒ ¼ö ÀÖ´Â ¼Õ»óÀÌ Áõ°¡ÇÏ´Â ÀÌÂ÷ÀûÀÎ ÁøÇà »óÅÂ(Secondary progression with an increase in disability observable over 6 months) 3) 6°³¿ù°£ Áö¼ÓÀûÀ¸·Î º¸Çà ´É·ÂÀÌ ³ªºüÁ® °ÉÀ» ¼ö ¾øÀ» ¶§(Loss of ability to walk, with or without assistance, persistent for at least 6 months) ´Ù. Åõ¿©¹æ¹ý: ´Üµ¶ ¿ä¹ý ¡á °í½Ã °³Á¤ °í½Ã¹øÈ£(½ÃÇàÀÏÀÚ) °í½Ã Á¦2021-26È£(2021.2.1.) ¡á °í½Ã °³Á¤ »çÀ¯ ±³°ú¼, °¡À̵å¶óÀÎ, ÀÓ»ó¹®Çå, Á¦¿Ü±¹ º¸Çè±âÁØ, ÇÐȸÀÇ°ß µî ÂüÁ¶ÇÏ¿©, Åõ¿©´ë»óÀ» McDonald Áø´Ü±âÁØÀ» ÃæÁ·ÇÏ´Â Àç¹ß¿ÏÈÇü ȯÀÚ·Î È®´ëÇÏ°í Àç¹ßÀÌÀ强 ´Ù¹ß¼º°æÈÁõÀ» Àç¹ß¿ÏÈÇü ´Ù¹ß°æÈÁõÀ¸·Î ¿ë¾î Á¤ºñÇÔ. ¡á º¯°æ Àü °í½Ã¹øÈ£(½ÃÇàÀÏÀÚ) °í½Ã Á¦2016-110È£(2016.07.01.) Ãâó : °Ç°º¸Çè½É»çÆò°¡¿ø |